Compare Agilysys Inc (AGYS) vs BioNTech SE - ADR (BNTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilysys Inc vs BioNTech SE - ADR — how do they compare? Agilysys Inc trades at $109.27 (market cap $2.99B), while BioNTech SE - ADR trades at $89.4 (market cap $24.08B). The key difference: BioNTech SE - ADR is far larger — about 8.1× Agilysys Inc's market cap, and Agilysys Inc is trading nearer its 52-week high, BioNTech SE - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Agilysys Inc for 14 Days and BioNTech SE - ADR for 60 Days on average.
| AGYS | BNTX | |
|---|---|---|
Market Cap | $2.99B | $24.08B |
Volume | 248,231 | 1,260,630 |
Sector | Technology | Health |
52-Week High | $141.12 | $119.34 |
52-Week Low | $62.19 | $83.89 |
Typical Hold Time | 14 Days | 60 Days |
Enterprise Value | $2.88B | $7.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGYS trades at $109.26, up 4.03% today, with a bullish technical signal and strong analyst support. Recent earnings beats and a 100% buy rating from 9 analysts highlight positive momentum. The company reported record Q1 2027 revenue of $87.7 million and raised its full-year outlook, driven by subscription growth and new client deployments in the hospitality sector. Key resistance is at $109, with support near $103.
The outlook for AGYS is positive, with strong revenue growth and expanding profit margins projected for 2026. Risks include high valuation multiples and reliance on hospitality sector recovery. Upside to the $120.75 consensus price target appears achievable if execution continues.
BioNTech (BNTX) trades at $88.93, down 8.29% in the last session. The stock shows a neutral technical signal with mixed moving averages and oscillators, while fundamentals reflect declining revenue and negative profitability amid a transition from COVID-19 vaccine reliance. Recent news highlights clinical trial setbacks in colorectal cancer but positive lung cancer data, alongside site closures and insider selling by the CEO.
The outlook remains speculative, with high valuation multiples contrasting with persistent losses. Opportunities lie in the cancer pipeline's potential, but risks include execution delays, competitive pressure, and cash burn. Analyst consensus is bullish with a $121 price target, yet investors face volatility from binary clinical outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Agilysys Inc
Agilysys provides enterprise software and SaaS solutions for the hospitality industry. Its products specialize in point-of-sale, property management, and inventory systems for hotels, resorts, and cruise lines.
Read more on AGYS →About BioNTech SE - ADR
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including COVID-19. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies.
Read more on BNTX →
